Aktienanalyse zu Artiva Biotherapeutics Inc (ARTV)ARTVArtiva Biotherapeutics Inc

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications. It operates in the Healthcare sector.

Artiva Biotherapeutics is not a good buy right now due to significant financial losses and recent downgrades by analysts. The current price is $4.19, which is near the downgraded price target of $4 from Jefferies and Wedbush. The RSI is extremely low at 12.93, indicating oversold conditions, but the company's ongoing net losses, which reached $23.5 million in Q1 2026, and the discontinuation of its lead program due to safety concerns, present substantial risks. The main risk is the potential for further declines in share price given the negative sentiment and recent analyst downgrades.